A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

Viatris

Status and phase: Completed; Phase 4

Conditions: Schizophrenia

Treatments: Drug: Aripiprazole; Drug: Ziprasidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00634348

A1281110

Details and patient eligibility

About

The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder

Enrollment: 256 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients with schizophrenia or schizoaffective disorder
• At least a 6th grade reading level
• Males or females, between 18 and 70 years of age at the time of consent
• Subjects must have been hospitalized for no more than 14 consecutive days immediately prior to screening

Exclusion criteria

• Psychiatric disorder other than schizophrenia or schizoaffective disorder
• History of arrhythmia, heart attack, or heart failure

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

256 participants in 2 patient groups

Aripiprazole

Active Comparator group

Treatment:

Drug: Aripiprazole

Ziprasidone

Active Comparator group

Treatment:

Drug: Ziprasidone